NCT07217860Phase 3Active not recruiting

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

Study sponsor: Xenon Pharmaceuticals Inc. · XENE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-06Estimated
Enrollment · participants400Estimated
Source updated2026-10-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Enrolling by invitation. After: Active not recruiting.

Check registry source